Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
24/7 Wall Street7/9/2026Positive
CORT
Corcept Therapeutics IncorporatedNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.98B
P/E Ratio
273.35
EPS
$0.34
Beta
0.46
52W High
$94.77
52W Low
$28.66
50-Day MA
$69.16
200-Day MA
$60.85
Dividend Yield
—
Profit Margin
6.16%
Forward P/E
111.11
PEG Ratio
0.81
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Fundamentals
| Revenue (TTM) | $769.10M |
| Gross Profit (TTM) | $755.64M |
| EBITDA | $-6.93M |
| Operating Margin | -30.10% |
| Return on Equity | 7.17% |
| Return on Assets | -0.62% |
| Revenue/Share (TTM) | $7.40 |
| Book Value | $5.94 |
| Price-to-Book | 15.18 |
| Price-to-Sales (TTM) | 12.97 |
| EV/Revenue | 12.16 |
| EV/EBITDA | 99.13 |
| Quarterly Earnings Growth (YoY) | -21.60% |
| Quarterly Revenue Growth (YoY) | 4.90% |
| Shares Outstanding | $107.35M |
| Float | $89.94M |
| % Insiders | 11.54% |
| % Institutions | 75.56% |
Historical Volatility
HV 10-Day
25.96%
HV 20-Day
36.82%
HV 30-Day
41.87%
HV 60-Day
47.15%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($88.00 target)
1
Strong Buy4
Buy1
HoldLatest News
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
Zacks Investment Research6/18/2026Neutral
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.
GlobeNewsWire6/18/2026Neutral
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.
Newsfile Corp6/17/2026Neutral
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Zacks Investment Research6/8/2026Positive
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (Ame.
Business Wire5/29/2026Neutral
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Zacks Investment Research5/28/2026Positive
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. “Following issuan.
Business Wire5/27/2026Neutral
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research5/19/2026Positive
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Zacks Investment Research5/15/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026